Jarrod D Predina1, Andrew D Newton1, Christopher Corbett1, Leilei Xia1, Michael Shin1, Lydia Frenzel Sulfyok1, Olugbenga T Okusanya2, Keith A Cengel3, Andrew Haas4, Leslie Litzky5, John C Kucharczuk1, Sunil Singhal6. 1. Center for Precision Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Division of Pulmonology, Allergy, and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 5. Division of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 6. Center for Precision Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: sunil.singhal@uphs.upenn.edu.
Abstract
BACKGROUND: Macroscopic complete resection can improve survival in a select group of patients with malignant pleural mesothelioma. During resection, differentiating residual tumor from inflammation or scar can be challenging. This trial evaluated near-infrared (NIR) intraoperative imaging using TumorGlow (a novel NIR imaging approach utilizing high-dose indocyanine green and delayed imaging) technology to improve detection of macroscopic residual disease. METHODS: Twenty subjects were enrolled in an open-label clinical trial of NIR intraoperative imaging with TumorGlow (Indocyanine Green for Solid Tumors [NCT02280954]). Twenty-four hours before pleural biopsy or pleurectomy and decortication (P/D), patients received intravenous indocyanine green. All specimens identified during standard-of-care surgical resection and with NIR imaging underwent histopathologic profiling and correlative microscopic fluorescent tomographic evaluation. For subjects undergoing P/D (n = 13), the hemithorax was evaluated with NIR imaging during P/D to assess for residual disease. When possible, additional fluorescent lesions were resected. RESULTS: Of 203 resected specimens submitted for evaluation, indocyanine green accumulated within 113 of 113 of resected mesothelioma specimens, with a mean signal-to-background fluorescence ratio of 3.1 (SD, 2.2 to 4.8). The mean signal-to-background fluorescence ratio of benign tissues was 2.2 (SD, 1.4 to 2.4), which was significantly lower than in malignant specimens (p = 0.001). NIR imaging identified occult macroscopic residual disease in 10 of 13 subjects. A median of 5.6 resectable residual deposits per patient (range, 0 to 11 deposits per patient), with a mean size of 0.3 cm (range, 0.1 to 1.5 cm), were identified. CONCLUSIONS: TumorGlow for malignant pleural mesothelioma is safe and feasible. Excellent sensitivity allows for to reliable detection of macroscopic residual disease during cytoreductive surgical procedures.
BACKGROUND: Macroscopic complete resection can improve survival in a select group of patients with malignant pleural mesothelioma. During resection, differentiating residual tumor from inflammation or scar can be challenging. This trial evaluated near-infrared (NIR) intraoperative imaging using TumorGlow (a novel NIR imaging approach utilizing high-dose indocyanine green and delayed imaging) technology to improve detection of macroscopic residual disease. METHODS: Twenty subjects were enrolled in an open-label clinical trial of NIR intraoperative imaging with TumorGlow (Indocyanine Green for Solid Tumors [NCT02280954]). Twenty-four hours before pleural biopsy or pleurectomy and decortication (P/D), patients received intravenous indocyanine green. All specimens identified during standard-of-care surgical resection and with NIR imaging underwent histopathologic profiling and correlative microscopic fluorescent tomographic evaluation. For subjects undergoing P/D (n = 13), the hemithorax was evaluated with NIR imaging during P/D to assess for residual disease. When possible, additional fluorescent lesions were resected. RESULTS: Of 203 resected specimens submitted for evaluation, indocyanine green accumulated within 113 of 113 of resected mesothelioma specimens, with a mean signal-to-background fluorescence ratio of 3.1 (SD, 2.2 to 4.8). The mean signal-to-background fluorescence ratio of benign tissues was 2.2 (SD, 1.4 to 2.4), which was significantly lower than in malignant specimens (p = 0.001). NIR imaging identified occult macroscopic residual disease in 10 of 13 subjects. A median of 5.6 resectable residual deposits per patient (range, 0 to 11 deposits per patient), with a mean size of 0.3 cm (range, 0.1 to 1.5 cm), were identified. CONCLUSIONS: TumorGlow for malignant pleural mesothelioma is safe and feasible. Excellent sensitivity allows for to reliable detection of macroscopic residual disease during cytoreductive surgical procedures.
Authors: John Y K Lee; Jayesh P Thawani; John Pierce; Ryan Zeh; Maria Martinez-Lage; Michelle Chanin; Ollin Venegas; Sarah Nims; Kim Learned; Jane Keating; Sunil Singhal Journal: Neurosurgery Date: 2016-12 Impact factor: 4.654
Authors: Charlotte E S Hoogstins; Quirijn R J G Tummers; Katja N Gaarenstroom; Cor D de Kroon; J Baptist M Z Trimbos; Tjalling Bosse; Vincent T H B M Smit; Jaap Vuyk; Cornelis J H van de Velde; Adam F Cohen; Philip S Low; Jacobus Burggraaf; Alexander L Vahrmeijer Journal: Clin Cancer Res Date: 2016-06-15 Impact factor: 12.531
Authors: Jarrod D Predina; Andrew D Newton; Jane Keating; Eduardo M Barbosa; Olugbenga Okusanya; Leilei Xia; Ashley Dunbar; Courtney Connolly; Michael P Baldassari; Jack Mizelle; Edward J Delikatny; John C Kucharczuk; Charuhas Deshpande; Sumith A Kularatne; Phillip Low; Jeffrey Drebin; Sunil Singhal Journal: Ann Surg Date: 2017-09 Impact factor: 12.969
Authors: Elizabeth H Baldini; William G Richards; Ritu R Gill; Brian M Goodman; Olivia K Winfrey; Hannah M Eisen; Raymond H Mak; Aileen B Chen; David E Kozono; Raphael Bueno; David J Sugarbaker Journal: J Thorac Cardiovasc Surg Date: 2015-02-07 Impact factor: 5.209
Authors: Marc de Perrot; Ronald Feld; Natasha B Leighl; Andrew Hope; Thomas K Waddell; Shaf Keshavjee; B C John Cho Journal: J Thorac Cardiovasc Surg Date: 2015-10-19 Impact factor: 5.209
Authors: Olugbenga T Okusanya; David Holt; Daniel Heitjan; Charuhas Deshpande; Ollin Venegas; Jack Jiang; Ryan Judy; Elizabeth DeJesus; Brian Madajewski; Kenny Oh; May Wang; Steven M Albelda; Shuming Nie; Sunil Singhal Journal: Ann Thorac Surg Date: 2014-08-05 Impact factor: 4.330
Authors: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Andrew D Newton; Jarrod D Predina; Christopher J Corbett; Lydia G Frenzel-Sulyok; Leilei Xia; E James Petersson; Andrew Tsourkas; Shuming Nie; Edward J Delikatny; Sunil Singhal Journal: J Am Coll Surg Date: 2018-11-22 Impact factor: 6.113
Authors: Servando Hernandez Vargas; Susanne Kossatz; Julie Voss; Sukhen C Ghosh; Hop S Tran Cao; Jo Simien; Thomas Reiner; Sadhna Dhingra; William E Fisher; Ali Azhdarinia Journal: Clin Cancer Res Date: 2019-04-23 Impact factor: 12.531